Showing 6 posts of 6 posts found.


Gilead challenges Government over patents on preventative HIV drug Truvada

August 22, 2019
Research and Development, Sales and Marketing AIDS, CDC, Gilead, HIV, IP, PrEP, Truvada, government, patents

Gilead is challenging the US Government’s patents on PrEP drug Truvada. The Foster City firm has submitted a challenge to …


Court sides with Amgen in Sandoz’ challenge over patent on Enbrel

August 12, 2019
Sales and Marketing Enbrel, IP, Novartis Amgen, court, patent, pharma

A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel. …


Counterfeit drugs – countering the lies

February 4, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Counterfeit drugs, IP, counterfeit medicines, falsified medicines, intellectual property, law, legal, patent

As the Falsified Medicines Directive comes into effect in February 2019, Louis Goss fact checks ‘common sense’ claims on counterfeit …

Fewer patents being filed for novel infectious diseases and AMR diagnostic technologies; US leads, UK follows

October 17, 2018
Research and Development AMR, IP, intellectual property, patents

Fewer patents are being filed for point-of-care diagnostic technologies aimed at tackling infectious diseases and antimicrobial resistance (AMR), according to …

Health innovation system is broken and failing patients, new report argues

October 15, 2018
Sales and Marketing IP, industry, intellectual property, priofit, research

The pharmaceutical industry is incentivised to set high prices and deliver short-term returns to shareholders, rather than focusing on riskier, …


US applies pressure on Canada to stem cross-border generics flow

April 30, 2018
Sales and Marketing Canada, IP, US, biotech, drugs, pharma, pharmaceutical

The US has upped the ante against Canada to secure stronger border checks for pharmaceutical goods by adding the country …

Latest content